Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains

2 Feb 2022

Abstract excerpt

Although mRNA vaccines encoding the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) prevent COVID-19, the emergence of new viral variants jeopardizes their efficacy. Here, we assessed the immunogenicity and protective activity of historical (mRNA-1273, designed for Wuhan-1 spike protein) or modified (mRNA-1273.351, designed for B.1.351 spike protein) Moderna mRNA vaccines in 129S2...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Animal Virus Infections Studies
Share to SARS-CoV-2 and COVID-19 Research
Share to Viral gastroenteritis research and epidemiology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34846168
DOI: 10.1126/scitranslmed.abm3302

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strainsPMID 34846168Read ↗

Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strainsSemantic proximity Read ↗

Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in miceSemantic proximity Read ↗

Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in miceSemantic proximity Read ↗

mRNA-1273 and Ad26.COV2.S Vaccines Protect Against the B.1.621 Variant of SARS-CoV-2Semantic proximity Read ↗

mRNA-1273 and Ad26.COV2.S vaccines protect against the B.1.621 variant of SARS-CoV-2Semantic proximity Read ↗

SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen PreparednessSemantic proximity Read ↗

Effectiveness of a broad-spectrum bivalent mRNA vaccine against SARS-CoV-2 variants in preclinical studiesSemantic proximity Read ↗

Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants.Semantic proximity Read ↗

Comparative analysis of human immune responses following SARS-CoV-2 vaccination with BNT162b2, mRNA-1273, or Ad26.COV2.SSemantic proximity Read ↗

Immunogenicity and efficacy of mRNA COVID-19 vaccine MRT5500 in preclinical animal modelsSemantic proximity Read ↗

Domain-based mRNA vaccines encoding spike protein N-terminal and receptor binding domains confer protection against SARS-CoV-2Semantic proximity Read ↗

Immunogenicity and Protective Efficacy of a SARS-CoV-2 mRNA Vaccine Encoding Secreted Non-Stabilized Spike Protein in MiceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.